TriangleAldesleukin (NCT02133196)
Aldesleukin trial for Advanced Non-Small Cell Lung Cancer (NCT02133196). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for people aged 18–72 with metastatic or unresectable non-small-cell lung cancer that progressed after first-line systemic treatment. A tumor must be removable to grow immune cells; measurable cancer must remain.
The idea: grow selected tumor-infiltrating lymphocytes from the patient’s tumor, then return them after cyclophosphamide and fludarabine. Aldesleukin follows the infusion. Its dose depends on medical fitness; people over 66 cannot receive the high-dose regimen. Researchers assess safety and tumor regression.
This phase 2 study plans 85 patients. James Yang leads at NIH in Bethesda, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.